S&P 500   4,567.00
DOW   34,483.72
QQQ   393.82
S&P 500   4,567.00
DOW   34,483.72
QQQ   393.82
S&P 500   4,567.00
DOW   34,483.72
QQQ   393.82
S&P 500   4,567.00
DOW   34,483.72
QQQ   393.82
NASDAQ:MTCR

Metacrine News Headlines

$1.32
+0.04 (+3.13%)
(As of 11/30/2021 12:00 AM ET)
Add
Compare
Today's Range
$1.26
$1.36
50-Day Range
$1.14
$3.83
52-Week Range
$1.11
$11.00
Volume
1.32 million shs
Average Volume
491,294 shs
Market Capitalization
$36.06 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
-2.97

Media Mentions By Week



Metacrine Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

MTCR
News Sentiment

0.60

0.27

Average
Medical
News Sentiment

Media Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

MTCR Articles
This Week

1

2

MTCR Articles
Average Week

Get Metacrine News Delivered to You Automatically

Sign up to receive the latest news and ratings for MTCR and its competitors with MarketBeat's FREE daily newsletter.

Metacrine (NASDAQ:MTCR) News Headlines Today

SourceHeadline
MarketBeat logoMetacrine, Inc. (NASDAQ:MTCR) Short Interest Update
americanbankingnews.com - November 16 at 1:06 PM
streetinsider.com logoForm 10-Q Metacrine, Inc. For: Sep 30 - StreetInsider.com
streetinsider.com - November 12 at 5:35 PM
finance.yahoo.com logoMetacrine Reports Third-Quarter 2021 Results - Yahoo Finance
finance.yahoo.com - November 12 at 12:34 PM
globenewswire.com logoMetacrine Reports Third-Quarter 2021 Results - GlobeNewswire
globenewswire.com - November 11 at 12:51 PM
finance.yahoo.com logoMetacrine Reports Third-Quarter 2021 Results
finance.yahoo.com - November 11 at 12:51 PM
benzinga.com logoWhy Eli Lilly Shares Traded Higher Today - Benzinga
benzinga.com - November 3 at 1:48 AM
finance.yahoo.com logoWhy Eli Lilly Shares Traded Higher Today - Yahoo Finance
finance.yahoo.com - November 2 at 8:47 PM
globenewswire.com logoMetacrine Reports Topline Results for MET409 Phase 2a - GlobeNewswire
globenewswire.com - November 2 at 3:47 PM
finance.yahoo.com logoMetacrine Posts Data From MET409 Combination Trial In Diabetes, NASH Patients
finance.yahoo.com - November 2 at 3:47 PM
finance.yahoo.com logoMetacrine Reports Topline Results for MET409 Phase 2a Combination Trial In Patients with Type 2 Diabetes and NASH
finance.yahoo.com - November 2 at 10:46 AM
benzinga.com logoHow The Future Looks For Last Week's Biggest Losers: Vinco Ventures, Atea Pharmaceuticals And More - Benzinga
benzinga.com - October 25 at 10:57 PM
finance.yahoo.com logoHow The Future Looks For Last Week's Biggest Losers: Vinco Ventures, Atea Pharmaceuticals And More - Yahoo Finance
finance.yahoo.com - October 25 at 5:56 PM
finance.yahoo.com logoMid-Day Market Update: Snap Drops After Q3 Results; Creatd Shares Jump - Yahoo Finance
finance.yahoo.com - October 22 at 5:31 PM
seekingalpha.com logoMetacrine cut to neutral at H.C. Wainwright as company's NASH program ends - Seeking Alpha
seekingalpha.com - October 22 at 5:31 PM
finance.yahoo.com logoMetacrine Reports Interim Results for MET642 Phase 2a Trial in Patients with NASH and Announces a Strategic Re-Prioritization of Its Clinical Development Programs - Yahoo Finance
finance.yahoo.com - October 22 at 5:31 PM
seekingalpha.com logoMetacrine, Inc. 8-K Oct. 21, 2021 4:06 PM - Seeking Alpha
seekingalpha.com - October 22 at 12:31 PM
nasdaq.com logoPre-market Movers: PHUN, CRTD, MTCR, DWAC, SNAP… - Nasdaq
nasdaq.com - October 22 at 7:31 AM
globenewswire.com logoMetacrine Reports Interim Results for MET642 Phase 2a Trial - GlobeNewswire
globenewswire.com - October 21 at 4:28 PM
finance.yahoo.com logoMetacrine Reports Interim Results for MET642 Phase 2a Trial in Patients with NASH and Announces a Strategic Re-Prioritization of Its Clinical Development Programs
finance.yahoo.com - October 21 at 4:28 PM
finance.yahoo.com logo48 Biggest Movers From Friday - Yahoo Finance
finance.yahoo.com - September 27 at 10:44 AM
seekingalpha.com logoLeap Therapeutics, aTyr Pharma lead healthcare gainers; Silverback Therapeutics, Aerie Pharmaceuticals among major losers - Seeking Alpha
seekingalpha.com - September 16 at 12:39 PM
seekingalpha.com logoLAUR, LPTX, AERI and TWKS among after hours movers - Seeking Alpha
seekingalpha.com - September 15 at 8:48 PM
seekingalpha.com logoMetacrine dips on R&D day with high trading volume - Seeking Alpha
seekingalpha.com - September 15 at 8:48 PM
finance.yahoo.com logoCandel Therapeutics Announces Presentations of Key Clinical Data at AdMeTech and European Association of Neuro-Oncology Conferences in September 2021 - Yahoo Finance
finance.yahoo.com - September 9 at 10:20 PM
finance.yahoo.com logoMetacrine Achieves Full Enrollment for MET642 Phase 2a Trial in Patients With Nash
finance.yahoo.com - September 9 at 5:11 PM
finance.yahoo.com logoMetacrine to Host Virtual R&D Day for Analysts and Investors on September 15, 2021 - Yahoo Finance
finance.yahoo.com - September 9 at 2:19 AM
finance.yahoo.com logoMetacrine to Host Virtual R&D Day for Analysts and Investors on September 15, 2021
finance.yahoo.com - September 8 at 9:14 AM
finance.yahoo.com logoMetacrine to Present at H.C. Wainwright 23rd Annual Global Investment Conference
finance.yahoo.com - September 7 at 6:13 PM
streetinsider.com logoForm 8-K Metacrine, Inc. For: Aug 12 - StreetInsider.com
streetinsider.com - August 12 at 9:08 PM
globenewswire.com logoMetacrine Updates MET642 Clinical Development Milestone and - GlobeNewswire
globenewswire.com - August 12 at 4:07 PM
finance.yahoo.com logoMetacrine Updates MET642 Clinical Development Milestone and Reports Second-Quarter 2021 Results
finance.yahoo.com - August 12 at 4:07 PM
finance.yahoo.com logoMetacrine to Present New Preclinical Data in Inflammatory Bowel Disease (IBD) at European Crohn’s and Colitis Organisation (ECCO) 2021 Virtual Congress - Yahoo Finance
finance.yahoo.com - July 7 at 1:15 PM
globenewswire.com logoMetacrine to Present New Preclinical Data in Inflammatory Bowel Disease - GlobeNewswire
globenewswire.com - July 7 at 12:47 AM
finance.yahoo.com logoMetacrine to Present New Preclinical Data in Inflammatory Bowel Disease (IBD) at European Crohn’s and Colitis Organisation (ECCO) 2021 Virtual Congress
finance.yahoo.com - July 6 at 9:46 AM
globenewswire.com logoMetacrine and Its Partners to Present Data at the EASL International Liver Congress™ 2021 - GlobeNewswire
globenewswire.com - June 17 at 8:45 AM
finance.yahoo.com logoMetacrine and Its Partners to Present Data at the EASL International Liver Congress™ 2021
finance.yahoo.com - June 17 at 8:45 AM
streetinsider.com logoUPDATE: HC Wainwright Starts Metacrine Inc. (MTCR) at Buy - StreetInsider.com
streetinsider.com - June 14 at 6:51 PM
seekingalpha.com logoMetacrine initiated buy at H.C. Wainwright citing novelty in therapeutic platform - Seeking Alpha
seekingalpha.com - June 14 at 1:51 PM
seekingalpha.com logoMetacrine completes enrollment in mid-stage NASH trial
seekingalpha.com - June 4 at 2:28 PM
globenewswire.com logoMetacrine Achieves Full Enrollment for MET409 Phase 2a - GlobeNewswire
globenewswire.com - June 2 at 9:25 AM
finance.yahoo.com logoMetacrine Achieves Full Enrollment for MET409 Phase 2a Combination Trial in Patients With Type 2 Diabetes and NASH
finance.yahoo.com - June 2 at 9:25 AM
finance.yahoo.com logoMetacrine to Present at 2021 Jefferies Healthcare Conference - Yahoo Finance
finance.yahoo.com - May 28 at 8:40 AM
globenewswire.com logoMetacrine to Present at 2021 Jefferies Healthcare Conference - GlobeNewswire
globenewswire.com - May 26 at 8:11 AM
finance.yahoo.com logoMetacrine to Present at 2021 Jefferies Healthcare Conference
finance.yahoo.com - May 26 at 8:11 AM
finance.yahoo.com logoDid Metacrine, Inc. (NASDAQ:MTCR) Insiders Buy Up More Shares? - Yahoo Finance
finance.yahoo.com - May 22 at 2:16 PM
finance.yahoo.com logoDid Metacrine, Inc. (NASDAQ:MTCR) Insiders Buy Up More Shares?
finance.yahoo.com - May 22 at 2:16 PM
benzinga.com logoMid-Afternoon Market Update: Dow Rises 150 Points; VF Corp Shares Fall On Downbeat Earnings - Benzinga
benzinga.com - May 21 at 8:44 PM
finance.yahoo.com logoMetacrine Inc (MTCR) President & CEO Preston Klassen Bought $74,791 of Shares - Yahoo Finance
finance.yahoo.com - May 21 at 2:07 PM
seekingalpha.com logoMetracrine rises 10.27% after hours as CMO and CEO acquires shares - Seeking Alpha
seekingalpha.com - May 21 at 9:06 AM
seekingalpha.com logoMetacrine, Inc. 4 May. 20, 2021 6:55 PM - Seeking Alpha
seekingalpha.com - May 21 at 9:06 AM
Get Metacrine News Delivered to You Automatically

Sign up to receive the latest news and ratings for MTCR and its competitors with MarketBeat's FREE daily newsletter.

This page was last updated on 12/1/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.